Noritomo Shimada
Overview
Explore the profile of Noritomo Shimada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
1734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al.
Sci Rep
. 2025 Jan;
15(1):72.
PMID: 39747852
In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the...
2.
Hirano Y, Nouso K, Kariyama K, Hiraoka A, Shiota S, Wakuta A, et al.
Acta Med Okayama
. 2024 Oct;
78(5):377-386.
PMID: 39467656
We previously found that "albumin grade", formerly called the "ALBS grade," demonstrated significant capability for prognostic stratification in hepatocellular carcinoma (HCC) patients treated with lenvatinib. The purpose of the present...
3.
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, et al.
Oncology
. 2024 Oct;
:1-13.
PMID: 39396495
Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries...
4.
Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, et al.
Liver Cancer
. 2024 Sep;
13(5):522-536.
PMID: 39296620
Introduction: The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses of IMbrave-150 and...
5.
Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, et al.
Gastro Hep Adv
. 2024 Aug;
1(4):508-515.
PMID: 39132067
Backgrounds And Aims: Cirrhosis and hepatocellular carcinoma (HCC) are potentially fatal complications of chronic hepatitis C virus (HCV) infection. We investigated how compensated cirrhosis and a history of curatively treated...
6.
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, et al.
Target Oncol
. 2024 Apr;
19(4):645-659.
PMID: 38689194
Background: In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and...
7.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, et al.
Cancer Rep (Hoboken)
. 2024 Apr;
7(4):e2042.
PMID: 38577725
Aims: The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods:...
8.
Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, et al.
Liver Int
. 2024 Mar;
44(5):1108-1125.
PMID: 38517286
Introduction: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short-mid term in advanced tumours...
9.
Toyoda H, Tada T, Uojima H, Nozaki A, Chuma M, Takaguchi K, et al.
J Gastroenterol Hepatol
. 2024 Jan;
39(5):949-954.
PMID: 38291715
Background And Aim: While several predictive models for the development of hepatocellular carcinoma (HCC) have been proposed, including those for patients with chronic hepatitis C virus (HCV) infection who have...
10.
Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, et al.
Target Oncol
. 2024 Jan;
19(1):29-39.
PMID: 38252195
Background: Data concerning the use of lenvatinib in very old patients (≥ 80 years) are limited, although the incidence of hepatocellular carcinoma (HCC) in this patient population is constantly increasing....